Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients
Authors:
Open Access
- 28 July 2025
- journal article
- Published by Wiley in HemaSphere
- Vol. 9 (7) , e70176
Abstract
Ex vivo drug response profiling is emerging as a valuable tool for identifying drug resistance mechanisms and advancing precision medicine in hematological cancers. However, the functional impact of dysregulation of the epigenome and transcriptome in this context remains poorly understood. In this study, we combined ex vivo drug sensitivity profiling with transcriptomic and epigenomic analyses in diagnostic samples from 597 pediatric B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL) patients. Ex vivo resistance to antimetabolites (e.g., cytarabine, thioguanine), glucocorticoids (e.g., dexamethasone, prednisolone), and doxorubicin was independently associated with reduced relapse‐free survival (P < 0.05). Molecular profiling identified pretreatment DNA methylation and gene expression patterns distinguishing resistant from sensitive cases, revealing key drug resistance signatures. These included aberrant expression of genes related to heme metabolism (e.g., ATPV06A) and KRAS signaling (e.g., GS02). Notably, we also observed atypical expression of genes usually restricted to T cells and other immune cells (e.g., ITK) in resistant BCP‐ALL cells. Our findings demonstrate that ex vivo drug response patterns are predictive of clinical outcomes and reflect intrinsic molecular states associated with drug tolerance. This integrative multi‐omics approach highlights potential therapeutic targets and underscores the value of functional precision medicine in identifying treatment vulnerabilities in pediatric ALL.Keywords
All Related Versions
This publication has 90 references indexed in Scilit:
- Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90Journal of Clinical Oncology, 2010
- Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemiaLeukemia, 2009
- Allele-specific gene expression patterns in primary leukemic cells reveal regulation of gene expression by CpG site methylationGenome Research, 2008
- Mutation of Genes Affecting the RAS Pathway Is Common in Childhood Acute Lymphoblastic LeukemiaCancer Research, 2008
- The fluorometric microculture cytotoxicity assayNature Protocols, 2008
- Treatment‐related death in childhood acute lymphoblastic leukaemia in the Nordic countries: 1992–2001British Journal of Haematology, 2005
- Increased in vitro cellular drug resistance is related to poor outcome in high‐risk childhood acute lymphoblastic leukaemiaBritish Journal of Haematology, 2003
- Gene Ontology: tool for the unification of biologyNature Genetics, 2000
- In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia.1997
- Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia.1992